Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations-Reference-Cited by-同舟云学术

Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations

Published:2023-10-21 Issue: Volume: Page:
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Zhao Ming^ORCID,Guo Zhi,Zou Ying-Hua,Li Xiao,Yan Zhi-Ping,Chen Min-Shan,Fan Wei-Jun,Li Hai-Liang,Yang Ji-Jin,Chen Xiao-Ming,Xu Lin-Feng,Zhang Yue-Wei,Zhu Kang-Shun,Sun Jun-Hui,Li Jia-Ping,Jin Yong,Yu Hai-Peng,Duan Feng,Xiong Bin,Yin Guo-Wen,Lin Hai-Lan,Ma Yi-Long,Wang Hua-Ming,Gu Shan-Zhi,Si Tong-Guo,Wang Xiao-Dong,Zhao Chang,Yu Wen-Chang,Guo Jian-Hai,Zhai Jian,Huang Yong-Hui,Wang Wei-Yu,Lin Hai-Feng,Gu Yang-Kui,Chen Jin-Zhang,Wang Jian-Peng,Zhang Yi-Min,Yi Jun-Zhe,Lyu Ning

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-023-10599-6.pdf

Reference128 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249

2. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390

4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34

5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma;International Immunopharmacology;2024-10

2. Current Trends in Hepatocellular Carcinoma Therapies in China;Digestive Disease Interventions;2024-08-26

3. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma;Frontiers in Immunology;2024-08-09

4. Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2024-08

5. Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis;Frontiers in Pharmacology;2024-07-31